Abstract: An electrically conductive member includes an elongate body, which has at least one electrically conductive region. The electrically conductive region comprises a porous polymeric material coated with an electrically conductive material. A method of manufacturing the electrically conductive member includes the steps of extruding an elongate body of polymeric material, wherein at least one region of the elongate body is porous in nature; and coating the elongate body with an electrically conductive material, such that the electrically conductive material substantially coats the pores of the at least one region.

Abstract: A catheter assembly 10 comprises a first elongate tubular member 12 having a proximal end portion 14 defining a proximal end 15, a distal end portion 18 having an opening therein 20 and defining a distal end 22, and at least one lumen 24 defined between the proximal end 15 and the distal end 22. A second elongate tubular member 26 has a proximal end portion 28 defining a proximal end 30, a distal end portion 32 defining a distal end 34, and at least one lumen 36 defined between the proximal end 30 and the distal end 34. The second elongate tubular member 26 is received within the at least one lumen 24 of the first elongate tubular member 12, such that the distal end portion 32 of the second elongate tubular member 26 projects from the opening 20 in the distal end portion 18 of the first elongate tubular member 12 An elongate, shape-imparting element 38 is receivable in the at least one lumen 24, 36 of at least one of the first elongate tubular member 12 and the second elongate tubular member 26.

Abstract: A method of forming a flanged tubular member includes the steps of: positioning a tubular blank in a die; applying nominal pressure; closing the dies; and increasing pressure within the blank, thereby converting the tubular blank to a hydroformed member having the flange and a hem with a cavity therein. The die halves define: a die tubular cavity portion; a die hem cavity portion; and a die flange cavity portion. Upon closing the die halves with nominal pressure and then increasing pressure, (1) the blank is deformed within the die tubular cavity portion; (2) the flange is defined from a portion of the blank in the die flange cavity portion; and (3) at least an intermediate hem is defined in the die hem cavity portion.

Abstract: An electrically conductive member (10) includes an elongate body (11) which has at least one electrically conductive region (20). The electrically conductive region (20) comprises a porous polymeric material coated with an electrically conductive material. A method of manufacturing the electrically conductive member (10) includes the steps of extruding an elongate body of polymeric material wherein at least one region of the elongate body is porous in nature; and coating said elongate body with an electrically conductive material such that the electrically conductive material substantially coats the pores of said at least one region.

Abstract: An electrically conductive member (10) includes an elongate body (11) which has at least one electrically conductive region (20). The electrically conductive region (20) comprises a porous polymeric material coated with an electrically conductive material. A method of manufacturing the electrically conductive member (10) includes the steps of extruding an elongate body of polymeric material wherein at least one region of the elongate body is porous in nature; and coating said elongate body with an electrically conductive material such that the electrically conductive material substantially coats the pores of said at least one region.

Abstract: An electrically conductive member (10) includes an elongate body (11) which has at least one electrically conductive region (20). The electrically conductive region (20) comprises a porous polymeric material coated with an electrically conductive material. A method of manufacturing the electrically conductive member (10) includes the steps of extruding an elongate body of polymeric material wherein at least one region of the elongate body is porous in nature; and coating said elongate body with an electrically conductive material such that the electrically conductive material substantially coats the pores of said at least one region.

Abstract: A catheter handle 10 includes a handle body (12). A steering control mechanism (14) is displaceably carried on the handle body (12). An electrode sheath carrier (16) is carried on the handle body (12), the electrode sheath carrier (16) being displaceable at least relative to the steering control mechanism (14).

Abstract: A catheter handle (10) includes a handle body (12) having a proximal end (14) and a distal end (16) with a receiving formation (18) being defined at the distal end (16) for receiving a catheter arrangement. A steering control mechanism (22) is carried by the handle body (12), a steering device of the catheter arrangement being connectable to the steering control mechanism (22). At least one introducer zone (24) is defined by a part of the handle body (12) and is in communication with the distal end (16) of the handle body (12). A shape forming element is able to be introduced, in use, via the introducer zone (24) into a lumen of a catheter of the catheter arrangement received by the receiving formation (18).

Abstract: Sealant and potting formulations comprising a thioether-functional, oligomeric polythiol prepared by reacting together: (a) a compound having at least two thiol functional groups; and (b) a compound having triple bond functionality are disclosed.

Abstract: The present invention describes the use of radio-labeled antitumor drugs in the treatment of solid tumors by the method of administering a radio-labelled anticancer drug to a patient and imaging at least a part of the patient using Positron Emission Tomography imaging. The method is used to monitor delivery of antitumor drugs to tumors and may be used to predict the effectiveness of therapy with a particular antitumor drug or combination of antitumor drugs, to assess the effectiveness of modulators of cellular accumulation, to individualize therapy and to evaluate the effectiveness of antitumor drugs with respect to particular cancers. Particularly preferred drugs are labeled taxanes, e.g., 11C-paclitaxel and 11C-docetaxel, labeled anthracyclines, e.g., 11C-doxorubicin and 11C-epirubicin, and other radio-labeled drug, e.g. 11C-topotecan and 11C-mitoxantrone. The invention further describes antitumor drugs labeled with the radioactive label 11C and methods of preparing radio-labeled drugs.

Abstract: Film-forming compositions are disclosed that are substantially free of organic solvent. The film-forming compositions include a resinous binder and at least one water dilutable additive including the reaction product of (i) a reactant including at least one isocyanate functional group with (ii) an active hydrogen containing alkoxypolyalkylene compound. Also disclosed are multi-layer composite coatings that include such film-forming compositions and methods of applying such multi-component composite coatings to a substrate.

Abstract: An improvement relating to an infinitely variable ratio transmission having a pair of oppositely oriented variable diameter torque input and output pulleys is disclosed wherein the conical surfaces of the pulleys include a multiplicity of axially and circumferentially movable sprocket bars to accommodate the fixed length of an inextensible drive belt or chain wrapping about the pulleys.

Abstract: A method of preparing an organic sol of particles is provided. Steps include: a) providing a suspension of particles in an aqueous medium; b) adding an organic liquid to form an admixture where the concentration of particles in the admixture is less than or equal to 40 percent by weight; c) maintaining the admixture at a temperature and pressure and for a time sufficient to reduce the water content to less than 30 percent by weight while simultaneously adding a water-compatible organic liquid at a rate sufficient to maintain a concentration of particles in the admixture at less than or equal to 50 percent by weight; and d) adding at least one polymer while maintaining the admixture at a temperature and pressure and for a time sufficient to provide an organic sol of particles comprising 1 percent by weight or less of water.

Abstract: The present invention provides an improved multi-layer composite of two or more polymeric layers at least one of which is formed from a thermosetting composition. The composite includes at least a first polymeric layer formed on a substrate and a second polymeric layer over the first polymeric layer, wherein in the absence of a boron-containing compound, the first and second polymeric layers have poor interlayer adhesion. The improvement resides in the inclusion of at least one boron-containing compound in one or both of the first and second polymeric layers in an amount sufficient to improve the interlayer adhesion between the first and second polymeric layers. Also provided is an improved curable coating composition used to form a multi-layer composite coating of two or more cured coating layers, at least one of which is formed from the thermosetting composition. Related methods and coated substrates are also provided.

Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.

Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.

Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analog which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analog compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.

Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.

Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier.

Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.